News
Bringing Hope to a Brave Fighter: Advanced Cancer Treatment at Bioocus Medical Group
At Bioocus Medical Group, we are proud to be treating a courageous patient from Pakistan who is battling Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL). This aggressive form of cancer requires advanced treatment, and we are committed to providing the best possible care through our cutting-edge therapies and compassionate support.
Bringing Hope to a Young Life: Advanced Leukemia Treatment at Bioocus Medical Group
At Bioocus Medical Group, we are dedicated to delivering cutting-edge cellular and gene therapies to patients worldwide. The story of Shakib Haytham Ghassan Abu-Hamdan, a 16-year-old boy from Jordan, exemplifies our commitment. Shakib is currently undergoing treatment for relapsed B-cell acute lymphoblastic leukemia (B-ALL) at our Cellular and Gene Therapy (CGT) Center at Tianjin Cancer Hospital Airport Hospital.
Bringing Hope to Young Lives: Advanced Cancer Treatment at Bioocus Medical Group
At Bioocus Medical Group, we are committed to delivering cutting-edge cellular and gene therapies to patients worldwide. A compelling example of this dedication is Emin, an 8-year-old boy from Russia, currently receiving treatment for Stage IV neuroblastoma at our Cellular and Gene Therapy (CGT) Center in Tianjin Cancer Hospital Airport Hospital.
The Importance of Regular Follow-Up and Check-Ups After Hematopoietic Stem Cell Transplantation
Post-transplant follow-up is crucial for hematopoietic stem cell transplant (HSCT) patients. Regular check-ups help detect issues like infections, graft-versus-host disease (GVHD), and relapse, ensuring early intervention and better outcomes.
CAR-T Therapy Overcomes Poor Prognosis in High-Grade B-Cell Lymphoma
A new study shows that CAR-T therapy can improve the prognosis for patients with high-grade B-Cell Lymphoma (HGBL), a subtype of large B-cell lymphoma, even in later treatment lines, offering new hope for these challenging cases.
Early Intervention with CAR-T Therapy for Large B-Cell Lymphoma Shows Promising Outcomes
A retrospective study comparing early versus late CAR-T therapy in large B-cell lymphoma patients reveals that earlier treatment may offer improved survival rates and fewer side effects, supporting its use as a second-line treatment.
CAR-T Therapy Shows Safety and Effectiveness in Cancer Patients with Autoimmune or Inflammatory Diseases
A recent study published in The Lancet Rheumatology demonstrates that CAR-T cell therapy is both safe and effective for treating lymphoma and multiple myeloma patients who also have autoimmune or inflammatory diseases, providing promising evidence for its broader application.
Breakthrough Insights into Genetic Subtypes of Adult B-ALL
A comprehensive review in Blood highlights recent advancements in the understanding of genetic subtypes of adult B-cell Acute Lymphoblastic Leukemia (B-ALL). The study explores biological heterogeneity, clinical implications, and the significance of precision medicine in improving patient outcomes.
Breakthrough Study Confirms Safety and Efficacy of CD19/CD20 CAR-T Therapy for r/r B-NHL
A phase 1 multicenter trial in China has demonstrated promising safety and efficacy of prizlon-cel, a dual-targeted CD19/CD20 CAR-T therapy, offering renewed hope for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
New Biomarkers Predict CAR-T Therapy Outcomes in Multiple Myeloma Treatment
A recent study published in Blood identifies soluble BCMA (sBCMA) levels and metabolic tumor volume (MTV) as potential biomarkers for predicting CAR-T therapy outcomes in relapsed and refractory multiple myeloma (RRMM) patients, paving the way for personalized treatment strategies.
CAR-T Therapy: A Promising Future for T-Cell Malignancies
CAR-T therapy, originally a breakthrough for B-cell malignancies, is showing promise in treating T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL). This evolving treatment faces unique challenges but recent clinical trials offer hope for new therapeutic solutions in T-cell malignancies.
Breakthrough Study Published in Blood: Nanobody-Based CD7 CAR-T Therapy for Acute Myeloid Leukemia
The Lu Daopei Medical Team achieves a groundbreaking advancement in treating Acute Myeloid Leukemia (AML) with their study on nanobody-based CD7 CAR-T therapy, published in the prestigious journal Blood.